Skip to content

D&A at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$2B+13.1%
LENSAR, Inc. logo
LENSAR, Inc.LNSR
$904K+7.1%
Schering-Plough logo
Schering-PloughSGP
$153K+126%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.28M+30.8%
Precision Optics Corporation logo
Precision Optics CorporationPOCI
$75.6K+21.2%
Bausch + Lomb logo
Bausch + LombBLCO
$101M-4.7%

Other financials

Income statement

See full
Revenue$30.9M-18.5%
Gross profit$23.5M-17.1%
Operating income-$17.8M-67.0%
Net income-$15.9M-93.9%
EPS (diluted)-$0.38-90.0%

Balance sheet

See full
Cash & equivalents$17.6M-37.2%
Total debt$10.8M-10.1%
Total equity$267.3M-4.3%
Total assets$304.0M-2.9%

Cash flow

See full
Operating cash flow-$10.9M-23.3%
CapEx$759.0K+32.0%
Free cash flow-$11.7M-23.8%

Valuation

See full
Market cap$232.23M-56.8%
Enterprise value$225.49M-55.7%
P/S1.8×-1.8×

Profitability

See full
Gross margin77%+5.1pp
Operating margin-43.4%+128pp
Net margin-36.6%-867pp
FCF margin-16.9%+4.9pp

Returns & leverage

See full
Return on equity-17.1%+12.6pp
Debt / equity0.0×
Current ratio10.2×-2.5×

Where this comes from

Reported directly by RxSight, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: RxSight, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about RxSight, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RxSight, Inc.'s D&A?
RxSight, Inc. (RXST) reported D&A of $834K in Q1 2026.
How has RxSight, Inc.'s D&A changed year-over-year?
RxSight, Inc.'s D&A increased by 7.5% year-over-year, from $776K to $834K.
What is the long-term trend for RxSight, Inc.'s D&A?
Over 4 years (2021 to 2025), RxSight, Inc.'s D&A has grown at a -4.8% compound annual growth rate (CAGR), from $3.98M to $3.27M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.